Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The Finnish company’s new factory has received the certification after being thoroughly audited by a recognized international entity.
July 23, 2024
By: Tim Wright
Editor-in-Chief, Contract Pharma
Nordic Bioproducts Group announced that its new manufacturing factory in Lappeenranta, Finland, has received the EXCiPACT certification to produce microcrystalline cellulose (MCC).
EXCiPACT is an independent, not-for-profit association that provides management oversight for the third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide. EXCiPACT selects independent, third-party accredited certification bodies that employ ISO 9001 qualified auditors who also meet EXCiPACT auditor competency requirements. This rigorous, independent certification system ensures compliance with GMP (Good Manufacturing Practice) and/or GDP (Good Distribution Practice) standards.
The company received the certification from ACT, one of EXCiPACT’s internationally recognized certification bodies, following a comprehensive audit. The certificate demonstrates that its site manufactures and distributes Microcrystaline Cellulose (MCC-AaltoCell) for the pharmaceutical industry according to the 2021 EXCiPACT Certification Standard for Pharmaceutical Excipient Suppliers.
In addition to the EXCiPACT certification, findings of an independent third-party LCA indicate that Nordic Bioproducts Group’s process also achieves a significant over 80% reduction in greenhouse gas emissions compared to traditional methods. Through responsible chemistry, reduced water and energy use, sustainable sourcing, and continuous production, Nordic Bioproducts Group aims to set a new standard in microcrystalline cellulose for pharmaceutical and nutraceutical products.
Featuring the world’s first continuous production line of up to 10,000 tons of MCC annually, the Lappeenranta factory was designed to ensure the highest level of quality, purity and sustainability in MCC production. Opened in spring 2024, Nordic Bioproducts Group is ramping up production to meet the needs of the pharmaceutical industry.
“We are thrilled to announce the EXCiPACT certification for our new Lappeenranta facility,” said Olli Kähkönen, CEO of Nordic Bioproducts Group. “We have designed our facility and processes to ensure quality and purity that not only meet but surpass the rigorous standards set by EXCiPACT. The certification underscores our dedication to the highest standards in our production processes.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !